As the fateful day to decide whether to resume trading between Osstem Implant and ShillaJen, which have been suspended due to embezzlement and breach of trust, is approaching within a week, investors are paying attention.



The Korea Exchange will decide whether Osstem Implant is eligible for listing eligibility substantive examination by the 17th.



Osstem Implant announced on the 3rd of last month that it had sued Mr. Lee, a money management employee, on charges of embezzlement on the job.



The exchange was originally scheduled to decide whether or not to be subject to substantive examination by the 24th of last month, but extended the preliminary examination period saying, "The impact on the market and social interest are large, so careful judgment is required."



If a person is subject to substantive examination, they are reviewed for 20 to 35 business days before being brought up to the Corporate Review Committee.



If it is not selected for screening, Osstem Implant's transaction will resume immediately the next day.



Osstem Implant announced last year's earnings on the 25th of last month, emphasizing that it generated a net profit of 32 billion won despite the embezzlement case.



Whether or not ShillaJen will be delisted will be decided by the KOSDAQ Market Committee until the 18th.




Earlier, on the 18th of last month, the KRX decided to delist ShillaJen at the Corporate Review Committee, which is the first stage of the listing substantive examination.



ShillaJen's stock trading has been suspended due to a substantive review for listing eligibility in May 2020 due to embezzlement and breach of trust by former and current executives, including former CEO Eun-Sang Moon.



In November of the same year, the committee granted an improvement period of one year, but in this review after the improvement period was over, the decision was made to delist.



At the time, an exchange official said, "After the new drug pipeline (development product line) decreased and the largest shareholder changed to M2N, 100 billion won came in. It is unclear whether the corporate value will be maintained." We need a concrete plan,” he said.



Shareholders are strongly opposed by accusing the CEO and executives of the exchange saying it is difficult to understand the exchange's decision.



(Photo = provided by Yonhap News TV, Yonhap News)